Form 4 for KAPA Kairos Pharma, LTD.
Accepted 2025-04-07 00:00:00 ET · period of report 2025-01-01 · accession 0001641172-25-002927 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-07 | 2025-01-01 | KAPA | Bhowmick Neil | CSO | A - Grant | $0.00 | +14.0K | 1.14M | +1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK | 2025-01-01 | A | A | 14,000 | $0.00 | 1,139,983 | D | — | — | (F1) Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof. (F2) Consists of (1) 1,130,650 shares of common stock and (2) 9,333 RSUs which remain subject to vesting. |